Cameron Turtle sold $1.4M of SYRE
Chief Executive Officer at Spyre Therapeutics, Inc.. 15,000 shares at an average of $92.01, traded Oct 1, 2026, filed Oct 2, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.4M at market
- 0Share of holdings soldSold 2.7% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001636282-26-000118, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -600 | $89.14 | $53k | 551,940 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -2,683 | $90.10 | $242k | 549,257 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -2,638 | $91.49 | $241k | 546,619 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -3,989 | $92.31 | $368k | 542,630 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -4,990 | $93.37 | $466k | 537,640 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $93.91 | $9,391 | 537,540 | 10 d ago |
Related signals
Other insiders at Spyre Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,000 shares | -26% | |
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.6M 28,933 shares | -91% | |
| 32Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,732 shares | -24% | |
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.5M 28,399 shares | -92% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.3M 15,000 shares | -3% | |
| 0Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $102k 2,500 shares | -2% | |
| 22Weak | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $435k 15,000 shares | -2% | |
| 30Weak | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.0M 45,000 shares | -6% | |
| 41Moderate | SYREsell Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $300k 18,428 shares | -16% | |
| 13Weak | Spyre Therapeutics, Inc. | Jeffrey W. Albers director | $246k 6,700 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.